Injections (subcutaneous semaglutide or tirzepatide) are the established, clinically studied route with predictable blood levels and robust weight-loss outcomes
The presence in the blood of LPS, from Gram negative bacteria, has long been considered a clear indicator of intestinal barrier dysfunction [71]
In April 2025 Pfizer was forced to discontinue a clinical trial with one of its experimental GLP-1 medicines to treat obesity due to potential drug induced liver injury found in one of the participants
Drugs for treating obesity
What it does is support the metabolic conditions insulin sensitivity, muscle function, mood, bone health that make weight loss more effective and sustainable when combined with a caloric deficit, adequate protein, resistance training, and (when appropriate) GLP-1 therapy